Michael P. Dwyer

Statistics

Publications

Citations

2.3K

H-Index

Active since

1972

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

WuXi AppTec (China)

United States Military Academy

The University of Texas at Austin

United States Pharmacopeial Convention

Michael P. Dwyer is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicinal chemistry, pharmacology, and drug discovery.

Publications per year

1972–2018

Publications

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

David Parry, Timothy J. Guzi, Nicole R. Davis et al. · Molecular Cancer Therapeutics · 2010 · 561 citations · Full text

Medicine, Oncology, Pharmacology +17

Enantioselective Intramolecular Cyclopropanations of Allylic and Homoallylic Diazoacetates and Diazoacetamides Using Chiral Dirhodium(II) Carboxamide Catalysts

Michael P. Doyle, Richard E. Austin, A. S. Bailey et al. · Journal of the American Chemical Society · 1995 · 215 citations

Natural Sciences, Chemistry, Catalysis +7

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

Kamil Paruch, Michael P. Dwyer, Carmen Álvarez et al. · ACS Medicinal Chemistry Letters · 2010 · 175 citations

Medicine, Oncology, Pharmacology +10

Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening

Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer et al. · Molecular Cancer Therapeutics · 2011 · 171 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Pharmacological Characterization of Sch527123, a Potent Allosteric CXCR1/CXCR2 Antagonist

Waldemar Gonsiorek, Xuedong Fan, David Hesk et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 130 citations

Life Sciences, Immunology, Pharmacology +17

1–5 of 34